Агвантар

Quick links to important sections

Агвантар

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Агвантар

Quick Facts: Агвантар (Levocarnitine)

Property Description
Active Ingredient Levocarnitine (L-Carnitine)
Pharmacological Class Metabolic Agent, Amino Acid Derivative
Forms Oral Solution, Tablet, Injectable Solution
Origin Naturally occurring substance (Endogenous)
General Purpose Supports fundamental energy and fat metabolism

Агвантар: Definition and Classification

Агвантар is a pharmaceutical preparation that provides the active substance Levocarnitine, which is classified as a metabolic agent and an essential amino acid derivative. This compound is naturally required for mammalian energy metabolism and is clinically recognized for its role in supporting cellular energy pathways. The product is precisely formulated to contain only the L-isomer of carnitine, which is the biologically active form that the body can readily utilize for critical cellular processes.

Composition, Origin, and Metabolic Role

Levocarnitine is a single-ingredient compound synthesized naturally in the body from other amino acids, but it is administered externally when internal synthesis is impaired or needs are increased. Агвантар is distinguished by its availability in multiple forms—including an easy-to-use oral solution, a solid tablet, and an injectable solution—offering flexibility for different patient needs. The molecule's general purpose is to act as a crucial carrier, essential for transporting long-chain fatty acids into the cell's mitochondria, thereby facilitating fat oxidation for energy. Supplementing Levocarnitine helps ensure the body can effectively utilize fat as fuel, a mechanism beneficial across various metabolic support scenarios.

What side effects are possible with Агвантар?

Possible Side Effects and Safety Information

The safety profile for Агвантар (Levocarnitine) is documented through official governmental regulatory sources and classifies adverse reactions by frequency and affected body system. This section summarizes the safety data without providing medical advice or instructions for use.

Adverse Reactions by Frequency and System

Classification Examples of Documented Side Effects
Common Nausea, vomiting, abdominal cramps, diarrhea, headache, and a drug-related body odor. These are primarily gastrointestinal reactions.
Less Common Dizziness, depression, high blood pressure (hypertension).
Rare Seizures.

Serious Adverse Reactions

Official regulatory labeling highlights the potential for two key serious adverse reactions:

  • Seizures: Reported in some patients, including an increased risk of frequency or severity in individuals with a pre-existing seizure disorder.
  • Serious Hypersensitivity: Immediate reactions such as anaphylaxis, laryngeal edema, bronchospasm, rash, and facial edema have been documented, especially with IV administration in certain populations.

Safety Considerations and Restrictions

The label defines specific constraints and monitoring needs:

  • Renal Impairment/ESRD: Chronic administration of high oral doses is restricted in patients with severe kidney dysfunction due to the potential accumulation of toxic metabolites (TMA and TMAO).
  • Pregnancy and Lactation: The medicine is categorized as Pregnancy Category B, indicating use should only occur if clearly needed. The medication is known to pass into breast milk.
  • Drug Monitoring: Patients taking warfarin (a blood thinner) concurrently with Агвантар require mandatory monitoring of their International Normalized Ratio (INR) levels following the start of treatment or any dosage change.

Overdose and Emergency Response

Overdose Manifestations and When to Seek Help

Official regulatory labeling indicates that there have been no documented reports of toxicity specifically resulting from acute overdosage of Агвантар (Levocarnitine). The only clinical manifestation noted in relation to the administration of very large doses is a gastrointestinal disturbance, specifically diarrhea.

Immediate Actions: In any suspected case of overdosage, patients are officially mandated to seek immediate medical attention or contact a poison control center.

Management and Antidote: Management of overdosage is focused entirely on general supportive measures and symptomatic treatment, as no specific antidote is known. A documented procedural option for managing high plasma concentrations is that Levocarnitine can be easily removed from plasma by dialysis.

Population-Specific Overdose Risk

A critical warning is specified for patients with severely compromised renal function or those undergoing chronic dialysis. Chronic high-dose oral administration in this population may lead to the accumulation of potentially toxic, nitrogenous metabolites, specifically trimethylamine (TMA) and trimethylamine-N-oxide (TMAO). This accumulation represents the most significant officially documented overdose-related constraint concerning specific patient populations. The overall regulatory profile defines the overdose scenario primarily by the absence of acute severe toxicity and the requirement for professional supportive medical intervention.

Therapeutic Uses of Агвантар

What Агвантар Treats: Main Uses and Benefits

The primary therapeutic benefit of Levocarnitine (Агвантар) is to provide supportive management for conditions linked to carnitine deficiency. The medication is applied in clinical settings that involve acute or unstable symptom patterns resulting from either genetic disorders or acquired deficiencies.

Агвантар is commonly used to help with specific severe conditions, including primary carnitine deficiency, certain inborn errors of metabolism, and carnitine loss associated with chronic hemodialysis. It helps address symptom clusters that may become intense or disruptive, such as profound muscle weakness, symptoms related to systemic imbalance, and chronic fatigue.

“This supportive care contributes to improved comfort during periods of heightened symptoms, especially those that interfere with routine activities.”

This supportive management may assist with maintaining functional stability and is generally part of long-term therapeutic care for these patient groups. It provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load related to physical stamina and energy.


Quick Fact: Supportive Management for Fatigue and Metabolic Stress

Context Benefit
Symptom Cluster Chronic fatigue and low physical endurance linked to carnitine deficit.
Common Scenario Supportive therapy for patients undergoing chronic hemodialysis due to carnitine loss.
Therapeutic Goal To support patients by easing the overall symptom burden related to muscle weakness and low energy.

Eligibility and Restrictions for Use

Who Can and Cannot Use Агвантар? — Official Regulatory Information

The eligibility for using Агвантар (Levocarnitine) is strictly defined by regulatory documents based on patient population and underlying health status.

Contraindications and Prohibited Use

Use is contraindicated for any patient with a known hypersensitivity to levocarnitine or any of the product's excipients. Furthermore, the use of certain oral solution formulations containing sorbitol is prohibited for patients diagnosed with Hereditary Fructose Intolerance (HFI).

Restrictions Based on Organ Function and Conditions

Population Group Regulatory Status
Severe Renal Impairment/ESRD The oral formulation is not recommended for chronic use due to the risk of potentially toxic metabolite accumulation. The safety of the oral form is not established in patients with renal insufficiency.
Seizure Disorders Use requires caution due to a documented risk of increased seizure frequency or severity.
Diabetes Use requires monitoring of plasma glucose levels, as levocarnitine may affect glucose utilization, necessitating adjustments to hypoglycaemic treatment.

Age and Reproductive Eligibility

Агвантар is approved for use in the adult population, as well as in pediatric populations including infants, children, and newborns, for labeled deficiency conditions. Use during pregnancy is restricted to when it is clearly needed; for lactating mothers, consideration must be given to discontinuing nursing or the medicine due to increased concentrations in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Агвантар (Levocarnitine)

Interaction scope

Category Information (Strictly from Regulatory Documents)
Medicinal product categories with documented interactions: Coumarin Anticoagulants; Hypoglycemic Treatments (Insulin or Oral); Anticonvulsants.
Specific interacting medicines (if explicitly listed): Warfarin, Zavegepant intranasal, Valproic Acid, Carbamazepine, D-Carnitine, DL-Carnitine.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic effects (coagulation/glucose); Exposure-Altering (plasma level reduction); Transporter-mediated caution (Zavegepant).
Population-specific interaction notes (if applicable): Patients with End-Stage Renal Disease (ESRD) on dialysis: Chronic oral administration risks accumulation of toxic metabolites (trimethylamine and TMA-N-oxide).

Interaction classifications (high-level)

Category Classification Details (Strictly from Regulatory Documents)
Interaction severity classification (as defined in official documents): Clinically Significant (Warfarin, Hypoglycemic Agents); Serious Restriction (Zavegepant intranasal); Exposure-Altering (Anticonvulsants).
Interaction-context constraints (as defined in official documents): Procedural Constraint: Mandatory requirement for International Normalized Ratio (INR) monitoring for patients taking warfarin. Mandatory requirement for plasma glucose monitoring when co-administered with hypoglycemic treatments.

Resulting interaction structure

Official interaction statements:

  • Co-administration with warfarin or coumarin anticoagulants has led to reports of increased INR.
  • A pharmacodynamic interaction with insulin or oral hypoglycemic treatments carries a risk of inducing hypoglycemia.
  • Chronic use of certain anticonvulsants is officially associated with decreased plasma concentrations of endogenous carnitine.
  • The use of D-Carnitine and DL-Carnitine is restricted as they may antagonize the L-Carnitine component.

Connection to the overall interaction profile (2–4 sentences):

The regulatory profile for Levocarnitine primarily details pharmacodynamic and exposure-modifying interactions that require mandatory procedural monitoring constraints for agents affecting blood coagulation or glucose control. The profile also clearly specifies a population-specific restriction for the chronic oral use of the medicine in patients with severe renal impairment, alongside restrictions on antagonistic carnitine substances.

Mechanism of Action

The action of Агвантар is centered on its role as a key metabolic cofactor that directly influences the pathway by which cells, especially those in muscle and heart, mobilize and metabolize lipid substrates. This mechanism leads to the stabilization of critical metabolic pathways and facilitates the clearance of metabolic inhibitors.

Facilitating Cellular Energy Generation

The drug facilitates the transport of long-chain fatty acids across the inner mitochondrial membrane, a process necessary for their breakdown (known as beta-oxidation). By serving as an essential cofactor in the Carnitine Shuttle System, the drug ensures that fat can be efficiently converted into ATP, the cell's main energy source. This engagement of the lipid-based energetic pathway results in enhanced substrate availability for ATP production** in myocardial and skeletal muscle tissue.

Clearance of Metabolic Byproducts

Агвантар supports cellular processes by binding to accumulating short- and medium-chain organic acids (acyl-CoA esters), which are products of metabolism. This action forms transportable acylcarnitines, facilitating their removal from the cell. The subsequent clearance of these metabolic intermediates reduces the concentration of compounds known to inhibit key enzymes and modulates the cellular metabolic environment.

Dosage and Administration Information

How Агвантар is Used: Official Administration Guidelines

The administration of Агвантар (Levocarnitine) is governed by specific instructions detailing the route, dosage, and intake conditions based on the patient's clinical state. This medication is available for Oral use, primarily as a solution or tablet for long-term maintenance, and for Intravenous (IV) administration, typically reserved for acute episodes or during renal therapy.

Dosing and Frequency

The official dosing for adults typically ranges from 1 g to 3 g per day when taken orally. The total daily oral dose must be divided and administered in evenly spaced portions throughout the day. For severe acute metabolic crises, the IV protocol involves a 50 mg/kg initial dose, followed by a maintenance dose administered every three to four hours over a 24-hour period. Specialized dosing is mandated for patients on hemodialysis, who receive an IV bolus of 10 to 20 mg/kg of dry body weight after each session.

Contextual Administration

Oral doses are required to be taken during or immediately following meals to optimize tolerance. The oral solution may be mixed with drinks or liquid food but must be consumed slowly. Intravenous administration protocols stipulate that the injection must be given as a slow 2 to 3 minute bolus or via infusion after dilution with compatible parenteral solutions, such as 0.9% Sodium Chloride. Chronic oral use is generally not recommended for patients with end-stage renal disease due to constraints concerning non-active metabolite accumulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Агвантар

Evidence for Use in Primary Systemic Carnitine Deficiency (PCD)

The evaluation of Агвантар (Levocarnitine) for the management of primary systemic carnitine deficiency is based on a body of documented clinical experience and established regulatory reviews. Research into this rare, genetic condition primarily involves case reports, biochemical studies, and observational settings evaluating daily-life functioning, rather than large-scale randomized controlled trials (RCTs), which are impractical for such rare diseases. Studies monitor specific outcomes and track major clinical events. Findings describe patterns observed in these studies, which describe the evaluation of carnitine supplementation in supporting necessary plasma and tissue levels. The evidence base provides limited insight into specific, standardized, long-term functional outcomes.

Evidence for Use in Secondary Carnitine Deficiency

Research examining carnitine deficiency arising from specific inborn errors of metabolism (IEMs) involves specialized case series and biochemical analyses. These studies explored research contexts involving fluctuating symptoms in patients, mostly infants and children. Findings indicate patterns related to the measurement of metabolite clearance in the studies. The research explores its use for conditions where symptoms may vary in intensity. Since each IEM is ultra-rare, the sample sizes were modest in the research, and data for these different groups remain insufficient for broad conclusions.

Evidence for Use in Chronic Hemodialysis

The evidence for patients with end-stage renal disease (ESRD) undergoing chronic hemodialysis is supported by multiple Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Research explored short-term symptom changes, focusing on outcomes related to physical discomfort and low physical endurance. While research highlights changes measured in plasma carnitine levels, findings were mixed across studies for certain clinical outcomes. For example, data show patterns related to changes observed in muscle symptoms in some analyses, but research describing changes in cardiac function are often reported as inconsistent. Comparative evidence is lacking for some specific subgroups, and there is limited information for long-term outcomes beyond one year.

Frequently Asked Questions (FAQ)

Common questions about Агвантар (FAQ)


Q: What is the main reason a doctor would prescribe Агвантар?

Official regulatory documents describe the role of Агвантар (Levocarnitine) as the treatment for primary systemic carnitine deficiency. It is also indicated for secondary carnitine deficiency, which can result from inborn errors of metabolism, and to address carnitine deficiency in patients with end-stage renal disease who are on chronic hemodialysis.


Q: Does Агвантар need to be taken long-term for its effects?

According to the official product information, Агвантар is indicated for both the acute and chronic treatment of carnitine deficiencies. This suggests that for many conditions, the medication is intended for long-term or ongoing management. However, there are restrictions regarding chronic oral use in people with severe kidney impairment.


Q: Can Агвантар cause weight changes or appetite changes?

Official patient safety information indicates that both changes in body weight and a loss of appetite have been reported as possible side effects of this medication.


Q: Are the side effects of Агвантар the same for everyone?

Regulatory documents list adverse reactions based on how often they occur in clinical settings (classified as common, less common, or rare). This classification shows that the experience and severity of side effects are expected to vary significantly among individuals who take the medication.


Q: Is Агвантар a narcotic or controlled substance?

According to official classification by regulatory bodies, the prescription formulation of Агвантар is not categorized as a controlled substance or narcotic medication.


Q: Is there a generic version of Агвантар available?

Yes, the active ingredient in Агвантар is Levocarnitine, and a generic version of the medication is available.


Q: Is it common to feel tired or dizzy when first starting Агвантар?

Official patient safety information lists dizziness as a less common side effect and also reports fatigue or loss of energy. These effects have been documented in the medication's safety profile.


Q: What should I know about taking Агвантар before driving or operating machinery?

Because dizziness is documented as a possible, less common side effect in the safety profile of Агвантар, this symptom is a factor that may affect one’s ability to drive or operate machinery.


Q: Does the time of day matter when taking Агвантар?

Official patient information states that the total daily dose should be administered in evenly spaced portions throughout the day. It also stipulates that oral doses are meant to be taken during or immediately following meals.


Q: What kind of studies have been done on the long-term use of Агвантар?

While specific details on the duration of clinical trials vary, the medication itself is indicated in official documents for the chronic treatment of carnitine deficiencies. This indicates a therapeutic goal that, in certain cases, involves long-term management.


Q: What happens if I forget a dose of Агвантар?

Regulatory patient information advises that if a dose is missed, it can be taken as soon as possible. If it is nearly time for the next dose, the missed dose should be skipped to continue the regular schedule. Doses should not be doubled or taken extra.


Q: Is Агвантар addictive or habit-forming?

The prescription formulation of Агвантар is not listed as a controlled substance by regulatory bodies. This classification is the standard regulatory proxy for whether a medication is considered addictive or habit-forming.


Q: Does Агвантар affect blood pressure or heart rate?

Both high blood pressure (hypertension) and a fast heartbeat (tachycardia) are included in the official safety profile for Агвантар. They are generally reported as less common side effects.


Q: How is Агвантар's effect explained in simple terms?

Агвантар provides the active substance Levocarnitine, which is a naturally occurring compound that helps the body convert fat into energy. This process is central to providing fuel to certain organs, including the heart, muscles, and brain.


Q: Is it necessary to finish the entire prescription of Агвантар?

Official patient information states that individuals continue the medication unless otherwise instructed by their healthcare team.


Q: Does taking Агвантар impact fertility?

Studies conducted in animals have not revealed any evidence that the medication impairs fertility. However, official labeling notes that adequate studies addressing fertility in humans are not available.


Q: Why is Агвантар prescribed as a secondary treatment sometimes?

Агвантар is specifically indicated for the treatment of 'secondary carnitine deficiency.' This type of deficiency is caused by underlying medical issues, often inborn errors of metabolism, where the body’s inability to process certain nutrients leads to the carnitine deficiency.


Q: Are there any specific laboratory tests required before starting Агвантар?

Patient information materials indicate that blood work or laboratory tests are often performed to measure carnitine levels in the blood. This typically occurs both before treatment begins and periodically throughout the course of use.


Q: Does taking Агвантар expire quickly?

Official information defines strict storage requirements, including keeping the product at controlled room temperature and away from light and heat. Furthermore, some oral solutions must be discarded 30 days after the bottle is first opened.


Q: How is the potential for overdose with Агвантар described in patient leaflets?

Patient leaflets and regulatory safety documents advise that immediate medical help should be sought if an overdose is suspected. This generally involves contacting a Poison Control Center or going to the nearest Emergency Room.


Q: Does Агвантар contain any ingredients that cause problems for people with allergies?

Official contraindication statements prohibit the use of the drug in anyone with a known hypersensitivity (severe allergy) to the active drug or any of its inactive ingredients (excipients). For example, the tablet form contains components such as magnesium stearate, microcrystalline cellulose, and povidone.


Q: Is it okay to crush or cut the Агвантар tablet, according to the manufacturer?

Patient information provided in certain regions suggests that the tablets may be crushed and mixed into water or soft food. This may be suggested for patients who experience difficulty swallowing the tablet whole.

How should Агвантар be stored and disposed of?

How to Store and Dispose of Агвантар

Official regulatory guidelines define strict environmental requirements for the storage and handling of Агвантар (Levocarnitine) to maintain product stability.

Storage Conditions

Агвантар must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with storage temperatures restricted from exceeding 30 C. It is mandatory to protect the product from freezing and to avoid excessive heat.

All forms must be stored away from moisture and protected from light; the injectable solution is specifically required to be kept in its original carton until use. The product must be stored out of the sight and reach of children.

Stability and Disposal

Stability limits apply once packaging is opened: any unused portion of a preservative-free injectable vial must be discarded. Some oral solutions must be discarded after 30 days of first opening. The disposal of expired or unused medicine must be performed in accordance with local regulatory requirements; do not discard the product via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Агвантар found in:

A-Z Index: